Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

被引：1

作者：

Zugasti, Ines ^{[1
,2
]}

Castano-Diez, Sandra ^{[1
,2
,3
]}

Esteban, Daniel ^{[1
,3
]}

Avendano Pita, Alejandro ^{[2
,4
]}

Pomares, Helena ^{[2
,5
]}

Perez Gonzalez, Ana ^{[2
,6
]}

Garcia-Avila, Sara ^{[2
,7
]}

Padilla-Conejo, Irene ^{[2
,8
]}

de la Fuente, Cristina ^{[2
,9
]}

Martinez-Roca, Alexandra ^{[1
,3
]}

Guijarro, Francesca ^{[1
,3
]}

Alamo Moreno, Jose Ramon ^{[1
,3
]}

Jimenez-Vicente, Carlos ^{[1
,3
]}

Cortes-Bullich, Albert ^{[1
,3
]}

Torrecillas, Victor ^{[10
]}

Guardia, Ares ^{[1
]}

Munarriz, Daniel ^{[1
]}

Carcelero, Esther ^{[1
]}

Suarez-Lledo, Maria ^{[1
,3
]}

Queralt Salas, Maria ^{[1
,3
]}

Lopez, Felix ^{[2
,7
]}

Ramos, Fernando ^{[2
,8
]}

Xicoy, Blanca ^{[2
,9
]}

Valcarcel, David ^{[2
,6
]}

Arnan Sangerman, Montserrat ^{[2
,5
,6
]}

Diez-Campelo, Maria ^{[2
,11
,12
]}

Martinez, Carmen ^{[1
,3
]}

Rovira, Montserrat ^{[1
,3
]}

Fernandez-Aviles, Francesc ^{[1
,3
]}

Esteve, Jordi ^{[3
,12
]}

Diaz-Beya, Marina ^{[2
,3
,12
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Grp Espanol Sindromes Mielodisplasicos GESMD, Madrid, Spain

[3] Inst Invest Biomed August Pi i Sunyer FRCB IDIBAP, Fundacio Recerca Clin Barcelona, Barcelona, Spain

[4] Hosp Univ Salamanca, Salamanca, Spain

[5] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[6] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[7] Hosp Mar, Barcelona, Spain

[8] Hosp Univ Leon, Leon, Spain

[9] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[10] Univ Barcelona, Barcelona, Spain

[11] Univ Hosp Salamanca, Salamanca, Spain

[12] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186777

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
Ines Zugasti
Monica Lopez-Guerra
Sandra Castaño-Díez
Daniel Esteban
Alejandro Avendaño
Helena Pomares
Ana Perez
Sara García-Ávila
Irene Padilla Conejo
Cristina de la Fuente Montes
Alexandra Martínez-Roca
Beatriz Merchán
Carlos Jiménez-Vicente
Francesca Guijarro
Jose Ramón Álamo
Albert Cortes-Bullich
Victor Torrecillas
Lucia Mont
Esther Carcelero
Gisela Riu
Lurdes Zamora
Joan Bargay
Ana Triguero
Maria Suarez-Lledó
Maria Queralt Salas
Felix López-Cadenas
Fernando Ramos
Blanca Xicoy
David Valcárcel
Montserrat Arnan
Carmen Martínez
Montserrat Rovira
Francesc Fernández-Avilés
Maria Díez-Campelo
Jordi Esteve
Marina Díaz-Beyá
Experimental Hematology & Oncology, 14 (1)
[2] Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Vinod Pullarkat
Keith W. Pratz
Hartmut Döhner
Christian Recher
Michael J. Thirman
Courtney D. DiNardo
Pierre Fenaux
Andre C. Schuh
Andrew H. Wei
Arnaud Pigneux
Jun-Ho Jang
Gunnar Juliusson
Yasushi Miyazaki
Dominik Selleslag
Martha L. Arellano
Chenglong Liu
Jean A. Ridgeway
Jalaja Potluri
Jovita Schuler
Marina Konopleva
Blood Cancer Journal, 15 (1)
[3] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
Montalban-Bravo, Guillermo
Short, Nicholas J.
Chien, Kelly S.
Valero, Yesid Alvarado
Daver, Naval
Borthakur, Gautam
Swaminathan, Mahesh
Maiti, Abhishek
Hammond, Danielle E.
Nogueras-Gonzalez, Graciela
Huang, Xuelin
Schneider, Heather
Shelly, Kristen
Kadia, Tapan M.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[4] Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia
Beran, M
LEUKEMIA RESEARCH, 2004, 28 (05) : 443 - 446
[5] Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
Vilorio-Marques, Laura
Fernandez, Christelle Castanon
Mora, Elvira
Gutierrez, Lorena
Bua, Beatriz Rey
Lorenzo, Maria Jose Jimenez
Beya, Marina Diaz
Pampliega, Miriam Vara
Molero, Antonieta
Sanchez-Garcia, Joaquin
Calabuig, Marisa
Cedena, Maria Teresa
Chen-Liang, Tzu
Santa, Johana Alejandra Diaz
Padilla, Irene
Hernandez, Francisca
Diez, Rosana
Asensi, Pedro
Xicoy, Blanca
Sanz, Guillermo
Valcarcel, David
Diez-Campelo, Maria
Bernal, Teresa
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[6] Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Bataller, Alex
Sasaki, Koji
Urrutia, Samuel
Montalban-Bravo, Guillermo
Bazinet, Alexandre
Chien, Kelly
Hammond, Danielle
Bouligny, Ian M.
Swaminathan, Mahesh
Issa, Ghayas
Short, Nicholas
Daver, Naval
DiNardo, Courtney D.
Kadia, Tapan
Jabbour, Elias
Ravandi, Farhad
Roboz, Gail J.
Savona, Michael
Griffiths, Elizabeth A.
McCloskey, James
Odenike, Olatoyosi
Oganesian, Aram
Keer, Harold N.
Azab, Mohammad
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD CANCER JOURNAL, 2025, 15 (01):
[7] Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults
Zandberg, Dan P.
Huang, Ting-Ying
Ke, Xuehua
Baer, Maria R.
Gore, Steven D.
Smith, Sheila Weiss
Davidoff, Amy J.
HAEMATOLOGICA, 2013, 98 (04) : 584 - 590
[8] Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Bewersdorf, Jan Philipp
Zeidan, Amer M.
CANCERS, 2021, 13 (07)
[9] Venetoclax plus Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes
Tan, Qi
Li, Zheng
Chen, Sifan
Cui, Qingya
Li, Mengyun
Zhao, Ye
Chen, Feng
Wu, Depei
Tang, Xiaowen
BLOOD, 2023, 142
[10] A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Sevilla, Juan Jose Rodriguez
Adema, Vera
Chien, Kelly S.
Ganan-Gomez, Irene
Montalban-Bravo, Guillermo
Urrutia, Samuel
Joseph, Joby
Yang, Hui
Borthakur, Gautam
Short, Nicholas J.
Issa, Ghayas C.
Kadia, Tapan M.
Takahashi, Koichi
Hammond, Danielle E.
Garcia-Manero, Guillermo
BLOOD, 2023, 142

← 1 2 3 4 5 →